Business
LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit
LOS ANGELES, CA - January 21, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De...
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"text","content":"LOS ANGELES, CA - January 21, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De La Soul and scheduled for Feb. 19 at Morehouse College in Atlanta. The Summit brings together leaders in health, culture, science, and community to advance health equity for Black men and families and is rooted in De La Soul's song "Good Health," written following the passing of founding member David Jolicoeur (Trugoy the Dove). Developed in collaboration with Blacksmith holdings, the program reflects De La Soul's evolution from musical pioneers to wellness advocates and will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness. LIXT said the Summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA, while creating a space to connect scientific innovation with communities most impacted by health disparities.","length":1198,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1293,"height":507,"url":"https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VCVJ6yC337nqarY7rX_X7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3NjtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MmFuzfq1hlGGX6FrBtdqXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDI7Y2Y9d2VicA--/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":1200,"height":471}}},{"type":"text","content":"To view the full press release, visit https://ibn.fm/0kkqK","length":58,"tagName":"p"},{"type":"text","content":"About LIXTE Biotechnology Holdings, Inc.","length":40,"tagName":"p"},{"type":"text","content":"LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commerci...